Pre-made Mirikizumab benchmark antibody ( Whole mAb, anti-IL23A/IL23 therapeutic antibody, Anti-IL23P19/P19/SGRF Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Mirikizumab biosimilar, Whole mAb, Anti-IL23A/IL23 Antibody: Anti-IL23P19/P19/SGRF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Mirikizumab (INN; development code LY3074828) is a human monoclonal antibody designed for the treatment of psoriasis.
| Products Name (INN Index) | Pre-Made Mirikizumab biosimilar, Whole mAb, Anti-IL23A/IL23 Antibody: Anti-IL23P19/P19/SGRF therapeutic antibody |
|---|---|
| INN Name | Mirikizumab |
| Target | IL23A |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Eli Lilly |
| Conditions Approved | NA |
| Conditions Active | Plaque psoriasis,Ulcerative colitis,Crohn's disease |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IL23A |
| Package |
